TFFP

TFF Pharmaceuticals, Inc. (TFFP) | Rumor.io

TFF Pharmaceuticals

TFFP

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about TFFP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Dec 23

$TFFP shareholder reports delayed sale of shares due to "close only mode".
No further details are provided about the reason for the delay.
The shareholder has been waiting for 5 days for the sale to be actioned.

Generated by AI

Sentiment

Of the messages about TFFP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +10.63
Bearish	—	—	—	0% -10.63

Dec 12

TFF Pharmaceuticals, Inc. ($TFFP) has seen a 50% surge since its first mention, with strong momentum and low float contributing to its success.
The company's partnership with Emory University and BARDA to develop a dry powder inhaled mRNA-based treatment for influenza and COVID has been a key factor in its growth, with Zacks upgrading it to a Strong Buy.
$TFFP has the potential for a major run, with only 4.44m shares outstanding and 24% of institutions holding shares, as well as the possibility of a buyout due to President Trump's deregulation plans and support from Barda.

Generated by AI

Topics

Of the messages about TFFP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	68%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	32%

Mar 20

TFF Pharmaceuticals, Inc. has announced a $1.2 million registered direct offering priced at-the-market under Nasdaq rules.
The company has secured $1.2 million in funding to support drug product development, with the gross proceeds expected to be used for general corporate purposes.
TFF Pharmaceuticals has also announced an update on its clinical programs, with the company's stock experiencing a trading halt and subsequent resumption due to volatility.

Generated by AI

Community

Of the messages about TFFP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	32.29%
Newcomers	—	—	100%	67.71%

Regulars· Dec 19

The company's phase 2 trials for TFF VORI and TFF TAC have shown positive initial data, with the PR describing the results as "remarkable" and providing "compelling evidence".
The stock will undergo a reverse split, leaving approximately 2.35 million shares outstanding, effective this morning.
The company's PR highlights the efficacy and safety data from the initial phase 2 trials, with the data showing "highly encouraging" results and providing "unequivocally positive" evidence.

Newcomers· Dec 23

New investors are bringing up concerns about the processing time for selling shares of TFF Pharmaceuticals, Inc. ($TFFP).
Some newcomers are discussing the potential reasons behind the delayed sales, including the company's actions in "close only mode".
There is a growing discussion among newcomers about the reliability and efficiency of TFF Pharmaceuticals, Inc. ($TFFP) in handling sell orders.

Generated by AI

Also Discussed

Investors talking about TFFP also mention

#	Name	Attention
1	INmune Bio Inc.INMB	0%0
2	PRVB - Provention Bio, Inc.	——
3	Perma-Fix Environmental Services, Inc.PESI	0%0
4	DMTK - DermTech, Inc.	——
5	IN8bio, Inc.INAB	0%0
6	MTEM - Molecular Templates, Inc.	——
7	Iridex Corp.IRIX	0%0
8	Akoustis Technologies Inc.AKTS	0%new
9	NRx Pharmaceuticals, Inc.NRXP	0%-0.01
10	Cue Biopharma, Inc.CUE	0%new